aTYR PHARMA (ATYR) EBT Margin (2019 - 2025)

aTYR PHARMA's (ATYR) quarterly EBT Margin came in at 15115.79% in Q3 2025, down 55.18% on a QoQ basis from 9740.85% in Q1 2024.

aTYR PHARMA (ATYR) EBT Margin (2019 - 2025) Analysis & Trends

aTYR PHARMA (ATYR) has 6 years of EBT Margin data on file, last reported at 15115.79% in Q3 2025.

Quarterly EBT Margin changed N/A year-over-year to 15115.79% in Q3 2025, while the trailing twelve-month figure through Mar 2026 was 41738.42% (changed N/A YoY) and the FY2025 annual result came in at 115698.42%, down 3394778.0% from the prior year.
EBT Margin eased to 15115.79% in Q3 2025, from 9740.85% in the prior quarter.
In the past five years, EBT Margin ranged from a high of 77.07% in Q4 2022 to a low of 15115.79% in Q3 2025.
A 4-year average of 7585.06% and a median of 7573.68% in 2023 frame the typical range for EBT Margin.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	41.75%
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	35.61%
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	35.71%
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-528.97%
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	18.33%
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	13.77%
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-25.06%
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-2.67%
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	12.09%
10	aTYR PHARMA	49.54 Mn	-7.87 Mn	-	-

Download Data